Pesquisar
ALX Oncology Holdings Inc
ALXOAdicionar à lista de desejos
1.940USD
-0.010-0.51%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
103.94MValor de mercado
PerdaP/L TTM
Mais detalhes de ALX Oncology Holdings Inc Empresa
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Informações de ALX Oncology Holdings Inc
Código da empresaALXO
Nome da EmpresaALX Oncology Holdings Inc
Data de listagemJul 17, 2020
CEOLettmann (Jason)
Número de funcionários80
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 17
Endereço323 Allerton Avenue
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone16504667125
Sitehttps://alxoncology.com/
Código da empresaALXO
Data de listagemJul 17, 2020
CEOLettmann (Jason)
Executivos da empresa ALX Oncology Holdings Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jason Lettmann
Mr. Jason Lettmann
Chief Executive Officer, Director
Chief Executive Officer, Director
263.61K
+19.23%
Dr. Corey S. Goodman
Dr. Corey S. Goodman
Executive Chairman of the Board
Executive Chairman of the Board
167.37K
--
Mr. Harish Shantharam
Mr. Harish Shantharam
Chief Financial Officer
Chief Financial Officer
78.00K
+3.85%
Ms. Shelly Pinto
Ms. Shelly Pinto
Senior Vice President - Finance, Chief Accounting Officer
Senior Vice President - Finance, Chief Accounting Officer
33.68K
-2.68%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
33.00K
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Dr. Alan Sandler, M.D.
Dr. Alan Sandler, M.D.
Director
Director
--
--
Mr. Chris H. Takimoto, M.D., Ph.D.
Mr. Chris H. Takimoto, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. Curran, M.D.
Dr. Daniel J. Curran, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jason Lettmann
Mr. Jason Lettmann
Chief Executive Officer, Director
Chief Executive Officer, Director
263.61K
+19.23%
Dr. Corey S. Goodman
Dr. Corey S. Goodman
Executive Chairman of the Board
Executive Chairman of the Board
167.37K
--
Mr. Harish Shantharam
Mr. Harish Shantharam
Chief Financial Officer
Chief Financial Officer
78.00K
+3.85%
Ms. Shelly Pinto
Ms. Shelly Pinto
Senior Vice President - Finance, Chief Accounting Officer
Senior Vice President - Finance, Chief Accounting Officer
33.68K
-2.68%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
33.00K
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de ALX Oncology Holdings Inc?
Os cinco principais acionistas de ALX Oncology Holdings Inc são: Mr. Jason Lettmann
Quantas instituições possuem ações da ALX Oncology Holdings Inc (ALXO)?
Em 2026Q1, 244 instituições possuíam ações da ALX Oncology Holdings Inc, com valor de mercado aproximado de 51.67M, representando 38.46% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -3929077.00.